Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII by Ponder, Katherine P & et al,




Evaluation of AAV-mediated gene therapy for
central nervous system disease in canine
mucopolysaccharidosis VII
Katherine P. Ponder
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Ponder, Katherine P. and et al, ,"Evaluation of AAV-mediated gene therapy for central nervous system disease in canine
mucopolysaccharidosis VII." Molecular Therapy.24,2. . (2016).
http://digitalcommons.wustl.edu/open_access_pubs/5516
original article Official journal of the American Society of Gene & Cell Therapy
Mucopolysaccharidosis VII (MPS VII) is a lysosomal stor-
age disease arising from mutations in β-D-glucuronidase 
(GUSB), which results in glycosaminoglycan (GAG) accu-
mulation and a variety of clinical manifestations including 
neurological disease. Herein, MPS VII dogs were injected 
intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna 
magna with AAV9 or AAVrh10 vectors carrying the canine 
GUSB cDNA. Although i.v. injection alone at 3 days of age 
resulted in normal cerebrospinal ﬂuid (CSF) GUSB activity, 
brain tissue homogenates had only ~1 to 6% normal GUSB 
activity and continued to have elevated GAG storage. In 
contrast, i.t. injection at 3 weeks of age resulted in CSF 
GUSB activity 44-fold normal while brain tissue homoge-
nates had >100% normal GUSB activity and reduced GAGs 
compared with untreated dogs. Markers for secondary stor-
age and inﬂammation were eliminated in i.t.-treated dogs 
and reduced in i.v.-treated dogs compared with untreated 
dogs. Given that i.t.-treated dogs expressed higher levels 
of GUSB in the CNS tissues compared to those treated i.v., 
we conclude that i.t. injection of AAV9 or AAVrh10 vectors 
is more effective than i.v. injection alone in the large animal 
model of MPS VII.
Received 20 May 2015; accepted 22 September 2015; advance online  
publication 10 November 2015. doi:10.1038/mt.2015.189
INTRODUCTION
Mucopolysaccharidosis type VII (MPS VII; Sly syndrome) is 
a rare lysosomal storage disorder arising from mutations in the 
β-glucuronidase gene (GUSB) and is inherited in an autosomal-
recessive manner.1,2 The GUSB enzyme is involved in the stepwise 
degradation of dermatan, heparan, and chondroitin sulfates, and 
its dysfunction results in the accumulation of these glycosamino-
glycans (GAGs).3 Clinical manifestations are more severe in MPS 
VII patients with little or no residual GUSB activity and include 
intellectual disability, hydrocephalus, hepatosplenomegaly, coarse 
facial features, dysostosis multiplex, heart valve disorders, and 
corneal clouding.1,4 Although intellectual disability is a hallmark 
of central nervous system (CNS) involvement, the underlying 
cause of cognitive impairment in MPS VII patients is not well 
understood. Chronic inflammation of the brain is thought to play 
a substantial role in many lysosomal storage disorders with CNS 
involvement including the mucopolysaccharidoses.5,6 In MPS VII, 
impaired autophagy associated with GAG storage and the second-
ary accumulation of GM2 and GM3 gangliosides generate cellular 
stress that induces an aggressive inflammatory response leading to 
a cascade of degenerative processes.5
Few approved clinical therapies exist for the treatment of 
MPS VII. Hematopoietic stem cell transplantation of allogeneic 
normal cells or gene-modified autologous cells has reduced neu-
rological symptoms in lysosomal storage disorder patients but 
still requires a conditioning procedure.7,8 Intravenous enzyme 
replacement therapy has recently been developed for MPS VII9–11  
but will probably not prevent neurological disease due to the 
blood–brain barrier. Although direct CNS delivery with enzyme 
replacement therapy is currently being pursued in clinical trials 
for other types of MPS (clinical trials identifier #: NCT02060526, 
NCT00884949), recombinant enzyme can only provide a short-
term effect, and repeated injections into the CNS will most likely 
be required. In contrast, gene therapy could provide long-term 
constitutive expression of a therapeutic gene and its protein prod-
uct after a single dose. However, enzyme levels in brain were only 
6% of normal in previous gamma retroviral-vector studies in neo-
natal MPS VII dogs that resulted in transduction of liver and high 
serum GUSB activity after intravenous (i.v.) administration.12,13 
Similarly, systemic injection of other vectors has not been very 
efficient at preventing storage in the murine brain (reviewed in 
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Ponder and Haskins14). Therefore, it is likely that delivery to the 
brain will be necessary to achieve an optimal effect.
Recently, adeno-associated viral (AAV) vectors with capsid 
proteins from serotype AAV9 and AAVrh10 (rh10) have demon-
strated the ability to enter the brains and to transduce neurons and 
glia of animals following i.v. injection,15–25 intrathecal (i.t. injec-
tion into the cerebrospinal fluid (CSF) via the lateral ventricle or 
the cisterna magna, or direct brain parenchyma injections.15,18,23–28 
However, a direct comparison of the efficacy of different serotypes 
given i.v. or i.t. has not been performed in canines, and the effect 
on a canine model of disease has not been determined. Therefore, 
our study aimed to discover the distribution of AAV-mediated 
GUSB expression in the CNS of dogs with naturally occurring 
MPS VII due to a missense mutation (R166H),29 and the effects on 
CNS lesions following i.v. and/or i.t. delivery using AAV serotypes 
AAV9 and rh10. This study demonstrates that i.t. is superior to i.v. 
delivery in MPS VII dogs, but i.v. injection is still able to reduce 
some biochemical and histochemical markers of disease.
RESULTS
Intravenous and intrathecal AAV9 and rh10 vectors 
were well tolerated
MPS VII dogs were treated with AAV vectors as detailed in Table 1 
and as described in the Materials and Methods. Animals designated 
as “i.v.-only” received i.v. injection of vector at 3 days of age, “i.t.-
only” dogs received i.t. injection of vector via the cisterna magna at 
3 weeks of age, and “i.v.+i.t.” dogs received i.v. injection of one vector 
at 3 days, and i.t. injection of the alternate vector at 2 months of age. 
CSF protein and cell counts were determined at 9 days postinjection 
and again at the end of the study period and were within normal lim-
its for all dogs (data not shown). All dogs were negative for anticapsid 
antibodies to AAV9 and rh10 in both serum and CSF at the start 
of the study (Supplementary Tables S1 and S2; Day 0). All treated 
dogs generated antibodies against the serotype used for treatment, 
which were much higher in serum than CSF regardless of the route of 
administration (Supplementary Table S1). Cross-reactive responses 
were also noted in serum in single-serotype treated dogs. Intriguingly, 
anticapsid antibodies found in the CSF of all i.t.-treated dogs did not 
indicate cross-reaction, and higher responses were observed against 
the rh10 than the AAV9 capsid (Supplementary Table S2).
Supraphysiological GUSB activity was found in CSF of 
i.t.-injected MPS VII dogs
All i.v.-only dogs had CSF GUSB activity ~1.7-fold normal at 6 
months postinjection (Figure 1a, red circles), and activity was 
relatively stable over the study period. In contrast, i.t.-only dogs 
had >250-fold normal CSF GUSB activity (normal CSF mean 
~10.7 U/ml) at peak expression, approximately 7 days postinjec-
tion (Figure 1a, blue squares). Activity declined slowly, resulting 
in average CSF GUSB activity of ~45-fold normal (445 ± 254 U/
ml) and ~42-fold normal (419 ± 151 U/ml), for AAV9 and rh10, 
respectively, at the end of the study. There were no differences 
between AAV9 and rh10 for i.t.-only dogs in levels of CSF activity 
or stability of expression (data not shown). i.v.+i.t.-treated dogs 
exhibited a slightly higher CSF activity at 6 months, with 137- and 
81-fold normal levels for i.v.-AAV9+i.t.-rh10 and i.v.-rh10+i.t.-
AAV9, respectively (Figure 1a, green diamonds). It is well known 
that circulating enzyme modified with mannose 6-phosphate 
(M6P) can be taken up by the M6P receptor on cells.30 The mea-
sured percentage of phosphorylated active CSF GUSB enzyme in 
the i.t.-only dogs was 40.8 ± 8.1%, which was not significantly dif-
ferent from values in normal dogs at 64.9 ± 4.6%.
Serum GUSB activity was also determined. Following i.v. 
injections, GUSB activity was ~30% of normal at 6 months of age 
in i.v.-only dogs. In contrast, serum GUSB activity of i.t.-only 
dogs was only ~1.7% of normal activity (Figure 1b). i.v.+i.t.-
injected MPS VII dogs had ~12% of normal serum GUSB activ-
ity (Figure 1b).
Normal GUSB activity and reduced GAG storage was 
found in the nervous tissue of i.t.-treated dogs
CNS tissue was harvested from all treated dogs at 6 months of age 
and biochemical assays performed on homogenates for GUSB 
activity, GAG levels, and total HEX activity. These data were 
compared with untreated MPS VII and normal control tissues. 
i.v.-only dogs had low GUSB activity in brain with <2% normal 
activity in the frontal, temporal, and occipital lobes and hippo-
campus (Figure 1c, top row, red circles). In comparison, i.t.-only 
dogs had average GUSB activity in cerebrum that was >95% of 
normal activity (Figure 1c, top row, blue squares). Deeper struc-
tures such as the hippocampus (195% normal) and brainstem 
Table 1 Study design and injection scheme of MPS VII dogs with recombinant AAV vectors
First injection Second injection
Animal ID# Group ID Agea (days) ROI Dose (GC/kg) AAV serotype Age (days) ROI Dose (GC/kg)c AAV serotype Gender
M2686 i.v.-only 3 i.v. 2 × 1013 AAV9 − − − − M
M2689 i.v.-only 3 i.v. 2 × 1013 rh10 − − − − F
M2729 i.t.-only 18 i.t. 5 × 1012 AAV9 − − − − F
M2757 i.t.-only 20 i.t. 5 × 1012 AAV9 − − − − M
M2760 i.t.-only 20 i.t. 5 × 1012 AAV9 − − − − M
M2739 i.t.-only 24 i.t. 5 × 1012 rh10 − − − − M
M2755 i.t.-only 20 i.t. 5 × 1012 rh10 − − − − F
M2685 i.v.+i.t. 3 i.v. 2 × 1013 AAV9 70 i.t. 2.8 × 1012 rh10 F
M2688 i.v.+i.t. 3 i.v. 2 × 1013 rh10 70 i.t. 5 × 1012 AAV9 M
aAge in days at time of injection.
−, not injected; F, female; GC/kg, vector genome copies per kilogram; i.t., intrathecal; i.v., intravenous; M, male; ROI, route of injection.
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(125% normal) also had elevated activity levels for i.t.-only dogs, 
which was not surprising given the close proximity of these 
structures to the ventricles and surrounding CSF. Results from 
i.v.+i.t. dogs resembled those found in i.t.-only dogs (Figure 1c, 
top row, green diamonds).
An increase in GAG concentration is a hallmark of the MPS 
disorders.12 To assess a therapeutic benefit, total GAG was mea-
sured. i.v.-only dogs had elevated GAGs compared to normal 
dogs (Figure 1c, middle row), which was significant in the fron-
tal lobe (P < 0.001), temporal lobe (P = 0.002), and brainstem 
(P = 0.006) and was not significantly lower than untreated MPS 
VII dogs in any region evaluated. In contrast to i.v.-only dogs, 
all CNS tissue collected from i.t.-only dogs exhibited lower 
GAG levels than untreated MPS VII dogs, which was significant 
in the frontal (P  < 0.001) and temporal (P = 0.004) lobes, 
the hippocampus (P  = 0.004), and the brainstem (P = 0.007) 
(Figure 1c). However, GAGs in i.t.-only dogs still remained ele-
vated compared to normal dogs in most brain tissues and was 
significantly higher compared to normal in the frontal lobe (P 
= 0.004). Again, results in i.v.+i.t.-treated dogs resembled those 
of i.t.-only dogs.
Elevation of other lysosomal enzymes such as HEX is another 
hallmark of MPS. Intriguingly, total HEX activity was reduced 
in the frontal, temporal, and occipital lobes for the i.v.-only dogs 
(Figure 1c, bottom row, red circles; P < 0.001 for all regions) and 
thus appeared to serve as a sensitive correlate for low levels of 
GUSB activity. HEX activity was also reduced in the i.t.-only and 
i.v.+i.t. dogs.
Figure 1 Circulating GUSB activity and biochemical analysis of nervous tissue. Nine MPS VII dogs were injected i.v.-only, i.t.-only, or i.v.+i.t. with 
AAV9 or rh10 vectors expressing the canine GUSB cDNA as detailed in Table 1. (a,b) CSF and serum were tested for GUSB activity at the indicated 
ages. Data are shown for individual animals except for i.t.-only dogs, where the means are plotted for each serotype (i.t.-AAV9, n = 3; i.t.-rh10, n = 2). 
The average value in normal dogs ± 1 SD is shown as a horizontal gray bar (n = 9), while untreated MPS VII dogs had <1 U/ml of GUSB activity (data 
not shown). Early CSF time points were not collected for i.v.-treated animals. (c) CNS tissues and peripheral nerve were collected at 6 months of age 
and tested for GUSB activity, GAG level, and HEX activity. The means of duplicates are recorded for individual animals for all assays, and the means of 
duplicates ± 1 SD are indicated with error bars for all i.t.-only dogs (n = 5; data for AAV9 and rh10 were pooled together). Values for normal dogs ± 
1 SD (gray-thatched horizontal bars, n = 3 to 9) and untreated MPS VII dogs (yellow horizontal bars, n = 3 to 7) are shown for each tissue. Black bars 
indicate the mean for each group. Arrows above the graph indicate when AAV-injections were given in reference to age and are as follows: i.v.-AAV 
(black arrow) at 3 days of age for i.v.-only and i.v.+i.t. dogs, i.t.-AAV (blue arrow) at 21 days of age for i.t.-only dogs, and i.t.-AAV (green arrow) at 
70 days of age for the i.v.+i.t. dogs. Statistical analysis was performed as indicated in Materials and Methods. Values in other groups were compared 
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GUSB activity is widely distributed in the cerebrum of 
i.t.-injected MPS VII dogs
To examine the distribution of enzyme activity, a histochemical 
GUSB activity stain was used. Normal dogs had diffuse activity 
throughout the cerebral cortex (Figure 2a,b) with activity found 
in the soma of cortical neurons (Figure 2c, solid arrowhead), 
while untreated MPS VII dogs were devoid of GUSB activity 
(Figure 2d–f). Both i.v.-only dogs had rare cortical neurons with 
substantial GUSB activity, which likely represented transduced 
cells (Figure 2g–l), but their frequency was estimated to be only 
~0.1%. GUSB activity was also identified in the leptomeninges.
In contrast, i.t.-only dogs displayed widespread GUSB activ-
ity in cerebral gray matter (Figure 2m,p). Staining extended 
into all layers of the cerebral cortex (layers I–VI) with intense 
focal activity in large pyramidal neurons (Figure 2n, o, q, and r). 
Transduction of neurons, likely in layer V, was more extensive 
in the i.t.-rh10 dogs (Figure 2n,q, black arrows) than for the i.t.-
AAV9 dogs, which is shown for several regions of the cortex in 
Supplementary Figure S1. GUSB staining in the i.v.+i.t. dogs 
(Figure 2s–x) resembled that of i.t.-only dogs. Supplementary 
Figures S2–S7 demonstrate that GUSB activity in the cortex is 
similar among the lobes evaluated and shows global activity for all 
of the treated dogs.
Considering the importance of restoring function to all 
regions of the brain, deeper sections of the brain were also 
analyzed for GUSB activity, as shown in Supplementary 
Figures S8–S10. i.v.-only dogs had detectable GUSB activity 
in the caudate nucleus (Supplementary Figure S8), the mid-
brain near the aqueduct (Supplementary Figure S9), the crus 
cerebri (Supplementary Figure S9), and CA3 neurons of the 
hippocampus (Supplementary  Figure S9). In the brainstem 
(Supplementary Figure S10), neuronal cell bodies positive for 
GUSB activity were scattered throughout gray matter, although 
specific nuclei were not identified. In addition, i.v.-only dogs had 
GUSB activity in the choroid plexus (Supplementary Figure 
S10), and along axons in the white matter (Supplementary 
Figure S10). The i.t.-only dogs had similar GUSB activity as the 
i.v.-only dogs in the caudate, midbrain near the aqueduct, brain-
stem, choroid plexus, and white matter, but clearly had much 
higher GUSB activity in the optic tract, crus cerebri, and hippo-
campus (Supplementary Figures S8–S10).
GUSB activity in the cerebral cortex was associated 
with reduced storage of secondary compounds and 
reduced inﬂammatory cell inﬁltrate
The accumulation of undegraded metabolites in many of the 
MPS disorders is associated with persistent activation of the 
lysosomes, astrogliosis, and inflammation.5 To assess prelimi-
nary therapeutic effects of AAV-mediated GUSB expression on 
storage material, sections of cerebral cortex were analyzed for 
Figure 2 GUSB stain of cerebral cortex. (a-x) Frozen sections of cerebrum from level R3 (Supplementary Figure S1) were stained for GUSB activ-
ity (red color) for samples collected at 6 months of age from animals treated as detailed in Table 1. The boxes in the top rows indicate the region 
shown at ×1 magniﬁcation, and the arrow in the middle rows indicate the region shown at higher power in the lower rows (at ×40). Scale bars are 
indicated.
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GM3 ganglioside, lysosomes, astrocytes, and microglia (Figure 
3). GM3 ganglioside is a secondary storage material that accu-
mulates in MPS VII brains31 and is apparent at 6 months of age 
in untreated MPS VII dogs (Figure 3b). Notably, low levels of 
GUSB enzyme in i.v.-only dogs were associated with a quali-
tative reduction in GM3 in cortical neurons (Figure 3c,d). In 
contrast, i.t.-only dogs showed near-complete resolution of 
GM3 ganglioside accumulation (Figure  3e,f). The intensity of 
LIMP2-positive vesicles was reduced in both i.v.- and i.t.-only 
dogs compared to those found in untreated MPS VII tissue, indi-
cating reduced lysosomal distension (Figure 3g–l). Astrogliosis 
in the cortex was markedly increased in untreated MPS VII dogs 
as shown by increased staining for GFAP (Figure 3n). i.v.-only 
dogs showed a reduced intensity in GFAP staining (Figure 3op), 
while i.t.-only and i.v.+i.t. dogs were similar to normal control 
dogs (Figure 3m,q,r). Microglia (Iba1-positive cells) are still 
present in treated dogs (Figure 3u–x) but appear to be reduced 
compared to untreated MPS VII tissue (Figure 3t). Some Iba1-
positive cells are present in normal animals (Figure 3s). Cerebral 
cortex staining for i.v.+i.t. dogs mirrors those patterns seen in 
i.t.-only dogs, and no serotype-specific differences were appar-
ent (data not shown).
Purkinje cells exhibit GUSB activity in AAV-treated 
MPS VII dogs
Cerebellar sections of a normal dog reveal diffuse GUSB activ-
ity in the molecular layer, Purkinje cells (PC), granular cell layer, 
and cerebellar white matter (Figure 4a,b). In stark contrast, MPS 
VII-affected dogs have no visible GUSB activity staining in the 
cerebellum (Figure 4c,d). Both i.v.-only dogs displayed sparse, 
focal activity in PCs and limited expression in the white matter 
(Figure 4e–h). i.t.-only dogs exhibited greatly enhanced expression 
throughout the cerebellar cortex (Figure 4i–l). The histochemical 
data correlate well with biochemical data, as GUSB activity was 
very high in the cerebellum at 3.1-fold normal in i.t.-only dogs, but 
only 0.03-fold normal in i.v.-only dogs (Figure 1c). Similar pat-
terns were observed for the i.v.+i.t.-injected dogs (Figure 4m–p) 
as for the i.t.-only dogs.
High-level GUSB activity found in the spinal cord of 
all treated dogs and sciatic nerve of i.t.-treated dogs
GUSB stain of spinal cord is shown in Figure 5. Untreated MPS 
VII dogs exhibited no GUSB activity throughout the spinal cord. 
i.v.-only dogs exhibited high-level GUSB activity throughout the 
gray matter, including strong focal staining in lower motor neu-
rons of the ventral horn, regardless of the AAV serotype. This 
correlated with biochemical GUSB activity throughout the spinal 
cord ranging from 15% at the cervical cord to 59% at the lumbar 
cord (Figure 1c, top row). GUSB activity was also seen through-
out the dorsal columns that house ascending sensory pathways. 
However, GAGs were elevated in the spinal cord in i.v.-only dogs 
compared with normal levels (Figure 1c; top versus middle row), 
which was significant in the thoracic (P < 0.001 versus normal, not 
significant versus untreated MPS VII) and the lumbar (P = 0.01 
versus normal, not significant versus untreated MPS VII) spinal 
cord. Elevated GAGs may be due to the absence of GUSB activity 
throughout the rest of the spinal cord (Figure 5). i.t.-only dogs 
had similar GUSB activity with histochemical staining in the 
lower motor neurons and dorsal columns as did i.v.-only dogs, 
but i.t.-only dogs also had positive GUSB staining in the lateral 
and ventrolateral funiculi. Biochemical GUSB analysis revealed 
>98% normal activity throughout the spinal cord. This diffuse 
GUSB activity may explain why GAGs were lower in the spinal 
cord of i.t.-only dogs compared with untreated MPS VII dogs, 
which reached significance in the thoracic (P < 0.001) and lumbar 
(P = 0.04) regions (Figure 1c).
i.v.+i.t. dogs had strong staining in the dorsal columns and 
lower motor neurons, as expected since i.v.-only dogs were posi-
tive in these regions. i.v.+i.t. dogs also had strong staining in 
the lateral corticospinal tract area (Figure 5, descending motor 
tracts), which was different from i.v.-only dogs. However, i.v.+i.t. 
dogs had relatively low levels of staining in the other regions of the 
spinal cord compared with i.t.-only dogs. There were no obvious 
differences in GUSB activity patterns between the two serotypes 
tested in this study.
Finally, the sciatic nerve also had enhanced levels of GUSB activ-
ity staining in i.t.-only dogs (Supplementary Figure S11), which 
Figure 3 Secondary storage, astrogliosis, and inﬂammatory 
responses are reduced in treated MPS VII cerebral cortex. Secondary 
storage was analyzed in cerebral cortex at 6 months of age by immuno-
histochemical staining in normal, untreated MPS VII (MPS VII), or MPS 
VII dogs that were treated with AAV vector of the indicated route and 
serotype. Staining was performed for a secondary storage ganglioside 
GM3 (a–f) lysosomal compartments were identiﬁed with lysosomal inte-
gral membrane protein LIMP2 (g–l) astrocytes were identiﬁed with glial 
ﬁbrillary acidic protein (GFAP) (m–r) and microglial cells were identi-
ﬁed with ionized calcium-binding adapter molecule 1 (Iba1) (s–x). Not 
all tissues were stained simultaneously, and many groups only had one 
dog, but normal and untreated control samples were performed for all 
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correlated with the biochemical GUSB data determined at 34% nor-
mal (Figure 1c). GUSB staining was noted in myelin sheaths and 
potentially axons of the sciatic nerve (Supplementary Figure S11). 
Sciatic nerve samples were not collected from other groups.
Biodistribution identiﬁes higher copy numbers in 
nervous tissue of i.t.-injected dogs
Vector copy numbers were determined with quantitative PCR 
on DNA extracted from tissues (Supplementary Figure S12). 
Low copy numbers were found in brain tissue of the two i.v.-only 
dogs (mean = 0.01 vector genomes/diploid genome (vg/dg)). 
Conversely, all i.t.-treated dogs had 100-fold higher average copy 
numbers in brain tissue (mean = 1 vg/dg), and similar values were 
identified among the different serotypes. In the spinal cord, vec-
tor copy numbers averaged >70-fold higher for i.t.-only compared 
with i.v.-only dogs. Systemic copy numbers were found at moder-
ate to low levels for most tissues in all treated groups, with liver tis-
sue having the highest copies. Here, average liver copies were 0.43 
vg/dg for i.v.-only dogs and 0.13 vg/dg for i.v.+i.t. dogs. Despite 
the fact that vector was only delivered to the CNS, vector was also 
detected in liver in i.t.-only dogs at 0.07 vg/dg; vector was also 
identified in heart, lung, kidney, and spleen for the i.t.-only dogs. 
These data are consistent with the low serum GUSB activity found 
in the i.t.-only dogs (Figure 1b).
Intravenous AAV reduces storage in non-CNS tissues
None of the groups had a significant reduction in urine GAGs at 
6 months of age compared with values in untreated MPS VII dogs 
(Figure 6a). However, i.v.-only dogs had a significant reduction 
in GAGs of the liver and renal medulla, and in HEX activity of 
liver, spleen, heart, and renal medulla (Figure 6b). In contrast, 
i.t.-only dogs did not have significant reductions in GAGs or total 
HEX in any somatic tissue that was analyzed (Figure 6b). Values 
in i.v.+i.t. dogs resembled those in i.v.-only dogs. GUSB activity 
staining confirmed the presence of active enzyme in liver and 
myocardium, confirming that biochemical activity was not due to 
blood contamination (Supplementary Figure S13). Thin sections 
indicated an absence of storage in liver and spleen of all i.v.-only 
and i.v.+i.t. dogs, with a partial reduction of storage lesions in i.t.-
only dogs (Supplementary Figure S14).
Clinical outcome in treated dogs
Although behavioral abnormalities have been documented in 
MPS VII mice, cognitive deficits have yet to be characterized in 
the canine model due to difficulties inherent in behavioral test-
ing performed in animals with limited mobility due to orthopedic 
disease.32,33 However, gait was evaluated in the treated dogs. While 
untreated MPS VII dogs were unable to stand or walk by 6 months 
of age (Supplementary Video S1), both i.v.-only dogs retained 
the ability to walk, albeit with mild (M2689) to moderate (M2686) 
gait abnormalities characterized by a shortened stride length and 
increased hock (tarsal joint) flexion of the hindlimb. The i.v.-
treated dog M2689 could also run. Three of five i.t.-only dogs 
(M2729, M2760, and M2739) were able to walk, although each 
showed markedly abnormal hock flexion and none could run, and 
M2755 and M2757 could not stand. Both i.v.+i.t. dogs (M2685 
and M2688) were able to run. Shortened stride length and exces-
sive hock flexion may be due to either joint/orthopedic disease 
Figure 4 GUSB activity in the cerebellum. Cerebellar sections collected at 6 months of age from normal, untreated MPS VII, or MPS VII dogs that 
were treated with AAV vectors of the indicated route and serotype were stained for GUSB enzyme activity (red color). The region indicated with a box 
at low power is shown at high power below it. GUSB-positive Purkinje cells (PC) soma are indicated in some panels. The granular cell layer (GCL) and 
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or peripheral nervous system dysfunction. No clear advantage 
among serotypes was seen.
DISCUSSION
I.V.-only MPS VII dogs have low GUSB expression in 
the CNS
I.V.-only MPS VII dogs received i.v. injection of 2E13 GC/kg 
of AAV vectors at day 3 of age, which resulted in limited GUSB 
expression by histochemical stains in cortical and hippocampal 
neurons, and Purkinje cells, while average expression levels in 
other brain tissues were only ~1 to 6% of normal with quantita-
tive assays of homogenates. Enzyme activity for the AAV9-treated 
dog was similar to that of the rh10-treated dog, although the small 
number of animals (N = 1) would make it difficult to identify small 
differences in efficacy. Higher doses were not given due to limited 
vector quantities. Our results differ from a study that reported very 
high (30% of normal) expression of N-acetylglucosaminidase-α 
in nonhuman primate CNS tissue after i.v. administration of an 
AAV9 vector,34 although quantification in this other study was 
confounded by the background enzyme activity present in these 
normal animals. Several other studies in nonhuman primates sup-
port our result that i.v. administration is not very efficient in large 
animals.15,20,28 It is also possible that accumulation of GAGs in the 
endothelium of blood vessels may inhibit the ability of AAV9 vec-
tors to cross the blood–brain barrier, as has been seen in MPS 
VII mice.35 However, this phenomenon has yet to be established 
in the MPS VII dogs. Although CNS GUSB activity was low and 
CNS GAG levels were not reduced in i.v.-only dogs, lysosomal 
HEX activity was normalized, and there was a reduction in GM3, 
LIMP2, GFAP, and Iba1 staining in the cortex. These results dem-
onstrate that relatively low levels of enzyme can indeed reduce 
markers of disease in the MPS VII brain, which is consistent 
with previous studies in MPS VII dogs with a gamma retroviral 
vector.13,36
In the spinal cord, motor neurons were clearly transduced 
in i.v.-only dogs, which is consistent with the relatively efficient 
transduction of motor neurons with AAV9 and rh10 vectors after 
i.v. injection.15,16,21,37 There was a progressive increase in GUSB 
activity from the cervical to the lumbar region of the spinal cord 
for unclear reasons, as has been noted in other studies.16,23
i.t.-only dogs have widespread GUSB activity in CNS 
tissues
i.t.-only dogs received 5E12 GC/kg of vector at 3 weeks of age via 
the cisterna magna, which resulted in supraphysiological expres-
sion throughout the brain and spinal cord. Histochemical staining 
revealed GUSB activity in neurons as deep as 2 mm from the sur-
face of the cortex and in Purkinje cells, while quantitative enzyme 
assays reported near-normal GUSB levels in CNS tissues at 6 
months of age. Enzyme activity was also high in neurons of the 
Figure 5 GUSB activity of the spinal cord. Frozen sections from the cervical, thoracic, and lumbar spinal cord of animals of the indicated groups 
were stained for GUSB activity (red color). Some regions of the cervical spinal cord were further imaged at higher magniﬁcation to show the motor 
neuron pools (blue arrow), dorsal column (green arrow), and descending motor tracts from the lateral funiculus (purple arrow) as indicated. All cord 
segments were oriented in the same direction with dorsal at the top and ventral at the bottom. Scale bars are indicated.
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hippocampus and unidentified nuclei of the brainstem, and these 
transduced neurons may transport enzyme to other parts of the 
brain via their axons. There was no significant difference in activ-
ity between AAV9 and rh10-treated dogs in quantitative GUSB 
assays. Although it appeared that the rh10 serotype might result 
in better transduction of neurons in Layer V of the cortex than the 
AAV9 serotype, too few dogs were evaluated to be conclusive, and 
both serotypes resulted in transduced cells in the deeper layers. 
Hinderer et al.27 also found high expression using an i.t.-AAV9 
vector, which generated fivefold normal α-l-iduronidase levels in 
the CNS of a feline model of Hurler syndrome.
Although GUSB activity was near normal in all regions stud-
ied and storage was eliminated in the cortex of i.t.-only dogs as 
assessed by GM3 and LIMP2 stain, total GAG levels were not 
normalized throughout the nervous system tissues. It is likely that 
some regions of the brain may fail to achieve sufficient enzyme 
activity to eliminate GAG accumulation. Indeed, this study showed 
that the caudate nucleus and some other deep regions had rela-
tively low GUSB activity with histochemical stains. Furthermore, 
some regions of the cortex and cerebellum were transduced less 
efficiently than other regions of the same tissue for individual dogs, 
which may relate to the ability of CSF to freely diffuse to the surface 
of a particular region. We are currently performing more detailed 
histochemical evaluations to determine if there are regions that 
accumulate storage. This study also showed that astrogliosis 
(GFAP) and activation of microglial cells (Iba1) was eliminated in 
the cortex of i.t.-only dogs. We are currently testing if reduction of 
these markers is seen throughout all areas of the brain.
i.t.-only dogs had high GUSB activity throughout the spinal 
cord, and a reduction in GAG levels compared with untreated 
MPS VII dogs. Transduction of lower motor neurons was likely 
responsible for the enzyme activity seen in some axons of the sci-
atic nerve, while activity in the surrounding myelin sheaths could 
be due to uptake from neurons that secrete enzyme or to direct 
transduction of Schwann cells; further studies will need to differ-
entiate between these possibilities. Overall, i.t.-only and i.v.+i.t. 
dogs had much higher activity in the spinal cord white matter 
tract regions than did i.v.-only dogs. Although specific areas were 
Figure 6 Systemic biochemical data. Samples were collected at 6 months of age. (a) Urine GAGs were normalized to the amount of creatinine in the 
sample using a dye-based binding assay. (b) Samples from liver, spleen, heart, and renal cortex (Renal C) and renal medulla (Renal M) were homog-
enized and tested for GUSB activity (top row), GAG levels (middle row), and HEX activity (bottom row). The means of duplicates are recorded for all 
assays for individual i.v.-only or i.v.+i.t.-treated dogs, while averages are shown for i.t.-only dogs ±1 SD (n = 5). Normal values ± 1 SD (gray-thatched 
horizontal bars, n = 9) and values for untreated MPS VII dogs ± 1 SD (yellow horizontal bars, n = 7) ranges are shown in all graphs. Values in the indicated 
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not identified, the areas with high enzyme activity likely include 
the lateral corticospinal tract containing axons from motor neu-
rons of the cortex, and possibly the rubrospinal tract containing 
axons from neurons of the red nucleus in the midbrain for i.v.+i.t.-
only dogs, while i.t.-only dogs had diffuse staining throughout the 
spinal cord white matter with higher activity at the edges of the 
tissue, coinciding with ascending tracts.
Effects of i.v.+i.t. treatment
This study showed that a single i.t. injection of either an AAV9 or 
rh10 vector at 3 weeks of age produced high levels of GUSB activ-
ity in the CSF and neuronal tissues of MPS VII dogs, but relatively 
low levels in serum, and only three of five i.t.-only dogs could walk 
at 6 months. In contrast, i.v. injections at 2 days of age resulted 
in greater systemic GUSB expression than i.t. administration, and 
both i.v.-only treated dogs could run at 6 months. In an attempt 
to treat both systemic and neurological disease, two dogs received 
both i.v. (at day 3) and i.t. (at 2 months with the other serotype) 
injections of AAV. Transduction still occurred in the CNS, and 
indeed, CSF GUSB in the i.v.+i.t. dogs was slightly higher after the 
6-month study period in comparison to the i.t.-only dogs. This 
may relate to the older age and larger body size when treated at 
2.3 months of age, leading to the total vector particles adminis-
tered that was threefold that used for the i.t.-only group treated at 
3 weeks of age. Here, the i.v.+i.t. group benefited from dual treat-
ment, as the CNS values mimicked the i.t.-only dogs’ GUSB levels 
and conversely, peripheral tissue values mirrored those seen in 
i.v.-only dogs and both dogs maintained mobility throughout the 
study. Peripheral tissue correction levels were also nearly identical 
in i.v.-only and i.v.+i.t. dogs, indicating that later i.t.-injections had 
no adverse effects on peripheral activity after i.v.-AAV injections. 
Although a slight reduction in urine GAGs was seen in i.v.-treated 
dogs, overall urine GAG levels were not corrected in any treat-
ment group. Indeed, even high GUSB serum levels in RV-treated 
dogs failed to completely correct urine GAGs.38 Similar vector 
copy numbers were also identified in all of the CNS tissues tested 
among i.t.-only and i.v.+i.t. groups (Supplementary Figure S12) 
indicating the feasibility of i.t. injections after i.v. administration 
if a different serotype is used. These data support that whole body 
correction may be obtained with i.v.+i.t. treatments using differ-
ent AAV vectors, although more detailed studies on peripheral 
tissues need to be done to establish the extent of improvement.
Expression is relatively stable in CSF for six months
In this study, i.v.-treated dogs had relatively stable GUSB activity 
at near-normal levels in CSF for six months, which is likely due to 
transduction of ependymal cells of the choroid plexus, with a pos-
sible contribution from transduced neurons. Similarly, i.t.-only 
dogs had relatively stable GUSB activity, although the level was 
much higher at 44-fold normal, expression from leptomeningeal 
cells probably occurred, and the contribution from neurons was 
much higher. Since dogs reach maturity at 6 months, and there 
is little replication in the adult brain, expression from the AAV 
vectors will likely be maintained long-term after i.t. administra-
tion. Indeed, we have now followed one dog for 16 months after 
i.t. injection and observed stable expression in the CSF (BL Gurda 
and ME Haskins, unpublished data).
Conclusions
In this study, we demonstrate that i.t. injection of recombinant 
AAV9 and rh10-serotyped vectors results in ~50-fold higher expres-
sion and a more profound effect on markers of disease than does 
treatment with the same vector given i.v.. Although i.v. administra-
tion was less efficient, it still reduced a secondary lysosomal enzyme 
and markers of astrogliosis and neuroinflammation and may exert 
a beneficial effect on neurological function, an aspect that was not 
studied here. In disease models with low therapeutic target levels, 
i.v.-only injections could potentially provide sufficient delivery to 
the CNS to achieve a therapeutic effect. However, in the case of MPS 
VII where high tissue activity is necessary, it appears that i.t. injec-
tions will be necessary for efficient treatment in the CNS. Overall, 
the therapeutic outcome and preliminary safety profiles generated 
here support further studies to advance AAV gene therapy for MPS 
VII and other CNS disorders into a clinical setting.
MATERIALS AND METHODS
Animals, AAV vector injections, and CSF collections.  The MPS VII 
dog colony is maintained at the National Referral Center for Animal 
Models of Human Genetic Disease at the School of Veterinary Medicine 
of the University of Pennsylvania. All protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University 
of Pennsylvania. For i.t. injections via the cisterna magna, the suboccipital 
region of propofol-anesthetized animals was punctured with a 22 gauge 
spinal needle. Following collection of 1–2 ml of CSF by gravity, 1–2 ml of 
vector in 0.9% sterile saline was injected over 1–2 minutes. Intravenous 
injections (1–2 ml volumes over 1–2 minutes) were performed via the 
cephalic vein. Treated dogs were sampled weekly for the first month and 
then monthly for the remainder of the study. For repeated CSF collections, 
dogs were anesthetized with propofol and 0.5–1 ml of CSF was collected 
by gravity flow from the cisterna magna as detailed above. After all proce-
dures, the animals were visually monitored closely over the next 48 hours. 
At the end of the study (6 months of age) euthanasia was performed with 
an i.v. overdose of pentobarbital (>80 mg/kg).
Treatment groups and study design. Animals designated “i.v.-only” 
received an i.v. injection of AAV9 (dog M2686) or rh10 (dog M2689) 
at 3 days of age. Animals designated “i.t.-only” received an i.t. injection 
of AAV9 (dogs M2739, M2757, and M2760) or rh10 (dogs M2729 and 
M2755) at 3 weeks of age. Animals designated “i.v.+i.t.” received i.v. injec-
tion of one vector at 3 days of age and i.t. injection of the alternate vector at 
2.3 months of age as detailed in Table 1. No adverse events were identified 
after i.v. or i.t. injection. Animals were euthanized at 6 months of age.
Vector production.  The vector genome encoded AAV2 i.t.Rs flanking a 
transcription unit containing the canine cDNA of GUSB29 under the con-
trol of a chicken β-actin promoter. The promoter used contained the cyto-
megalovirus enhancer with the β-actin promoter and a synthetic intron, 
which are 100% identical with nucleotide 721–2454 of Genbank39 acces-
sion number GI:388594935. The i.t.Rs were from AAV2 and are 100% 
identical with nucleotide 4660 to 4493 of GI:209616 (ref. 40). The plas-
mid was cross-packaged by the Institute of Human Gene Therapy at the 
University of Pennsylvania into AAV9 (ref. 41) and rh10 (ref. 42) capsids 
resulting in two recombinant viral vectors each containing the same single-
stranded AAV2-genome, and large-scale vector preparations were gener-
ated as previously described.41
Neutralizing antibody titers. Neutralizing antibody assays were per-
formed on Huh7 cells as previously described.43 Assays on CSF samples 
used sterile PBS as a transduction control. The lowest dilution for the assay 
was usually 1:5 for serum and CSF, although some samples began with a 
1:10 dilution due to low sample volume.
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DNA extraction and biodistribution studies. Total DNA from tissues was 
extracted using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA) and from 
ethylenediaminetetraacetic acid–treated blood samples using the QIAamp 
DNA Blood Mini Kit (Qiagen) following the manufacturer’s recom-
mended protocol. Real-time PCR (TaqMan Universal Master Mix; Applied 
Biosystems, Foster City, CA) was used to detect and quantify vector genomes 
in total DNA extracted from frozen samples as previously described,44 using 
primer and probe sets targeted to sequences within the nRBG polyad-
enylation signal (forward primer 5′-GCCAAAAATTATGGGGACAT-3′, 
reverse primer 5′-ATTCCAACACACTATTGCAATG-3′, probe 
6FAM-ATGAAGCCCCTTGAGCATCTGACTTCT-TAMRA).
Tissue processing and protein determination.  Tissue were homogenized 
as detailed in the Supplementary Materials and Methods section in sam-
ple buffer (0.9% NaCl, 0.2% Triton), and the supernatant of the lysate was 
used for protein, enzyme, and GAG assays.
Enzyme assay. Five to ten microliters of tissue homogenate, serum, or CSF 
was incubated in 200 μl of total volume with the appropriate substrate for 
1 to 3 hours at 37 °F, and the reactions stopped with 2 ml of stop buffer 
(0.32 mol/l of glycine, 0.2 mol/l of sodium carbonate, pH 10.5) as detailed 
in the supplemental methods. The fluorescence of the product (4-methyl-
umbelliferyl (4-MU)) was measured with the VersaFluor Fluorometer 
(Bio-Rad) at an excitation wavelength of 365 nm and an emission wave-
length of 450 nm. The enzyme activity was calculated from the standard 
curve of the 4-MU product of the reaction, with 1 unit defined as 1 nmole 
of substrate converted to product in 1 hour at 37 °F.
Glycosaminoglcyan assays. Tissue GAGs were assessed using the Blyscan 
sulfated GAG assay (Biocolor, Carrickfergus, Antrim, UK) using the man-
ufacturer’s suggested protocol with chondroitin-4-sulfate as the standard 
(Sigma, St Louis, MO). Depending on the tissue origin and genotype, 10 to 
50 μl of homogenate were assayed. The final value was calculated using the 
standard curve and normalized to protein concentration.
Mannose phosphorylation levels on GUSB. Soluble cation-independent 
mannose 6-phosphate receptor was coupled to affinity column media as 
previously described,45 and samples were applied to an equilibrated col-
umn, washed, and eluted with M6P as detailed in the Supplementary 
Materials and Methods. GUSB activity in unbound and bound fractions 
was determined using 4MU-β-glucuronide fluorescent substrate. These 
values were then used to calculate the percentage of mannose phosphory-
lation on GUSB enzyme.
Tissue preparation and histology.  Whole brain and spinal cord were 
extracted immediately following euthanasia. The brain was sectioned in 
the coronal plane into left and right hemispheres. Five transverse sections 
were evaluated from the frontal lobe (R0; Supplementary Figure S1) to 
the occipital lobe (R5). Pieces from the right hemisphere were frozen in 
optimal cutting temperature embedding media for cryosectioning, and 
sections were fixed and stained for GUSB activity as previously described46 
using an overnight incubation followed by a nuclear counterstain with 
methyl green from Vector Labs (Burlingame, CA). Sections from the left 
hemisphere were used for biochemistry and DNA copy analysis after flash 
freezing in liquid nitrogen as detailed above. Pieces from the cerebral lobes 
and the cerebellum contained some underlying white matter. Other pieces 
from the left hemisphere were used for immunohistochemistry.
For GM3 immunohistochemistry, brain slices were fixed overnight in 
4% paraformaldehyde/PBS, equilibrated sequentially in 15 and 30% sucrose, 
and frozen in optimal cutting temperature embedding medium. GM3 
immunostaining was performed as previously described27 using mouse 
monoclonal antibody DH2 (Glycotech, Gaithersburg, MD) followed by 
a biotinylated secondary antimouse antibody (Jackson Immunoresearch, 
West Grove, PA) and detection with a Vectastain Elite ABC kit (Vector Labs).
For immunostaining with GFAP, LIMP2, and Iba1, sections were fixed 
in formalin and embedded in paraffin, and 6-μm samples were treated for 
antigen retrieval as detailed.27 Primary antibodies used were rabbit antibodies 
against GFAP (glial fibrillary acidic protein; used at 1:1,000; Abcam Ab7260, 
Cambridge, MA) and LIMP2 (lysosomal integral membrane protein-2 used 
at 1:200; Novus Biologicals NB400-129, Littleton, CO), and goat antibody 
against Iba1 (ionized calcium-binding adaptor molecule 1; used at 1:100; 
Abcam Ab5076). Fi.t.C- or TRi.t.C-labeled donkey antirabbit or antigoat 
(Jackson Immunoresearch) served as secondary antibody. Samples used for 
thin sections were fixed and embedded in plastic as detailed27 and 1-μm 
sections were stained with toluidine blue.
Statistics. Values in different groups were compared using ANOVA with 
Holm–Sidak post hoc analysis if normality and equal variance tests passed, 
and with ANOVA on ranks with Dunn’s post-hoc analysis if those tests 
failed. *P = 0.01–0.05, **P = 0.001–0.01, ***P < 0.001. A P value of <0.05 
was considered significant.
SUPPLEMENTARY MATERIAL
Figure S1. Diagram of brain sectioning technique and examples of 
GUSB staining from different regions of the cerebral cortex for i.t.-
treated MPS VII dogs.
Figures S2. GUSB stain at 6 months of age at level R0 (cranial).
Figures S3. GUSB stain at 6 months of age at level R1 (just cranial to 
temporal lobe). 
Figures S4. GUSB stain at 6 months of age at level R2.
Figures S5. GUSB stain at 6 months of age at level R3.
Figures S6. GUSB stain at 6 months of age at level R4.
Figures S7. GUSB staining at 6 months of age at level R5 (occipital lobe).
Figure S8. GUSB stain of the caudate nucleus.
Figure S9. GUSB stain of the midbrain and hippocampus.
Figure S10. GUSB stain of the brainstem, choroid plexus, and white 
matter.
Figure S11. GUSB stain of sciatic nerve in i.t.-only treated dogs.
Figure S12. Biodistribution in AAV-treated MPS VII tissues.
Figure S13. GUSB stain of liver and left myocardial free wall (heart).
Figure S14. Thin sections of liver and spleen.
Table S1. Neutralizing antibody titers against AAV9 and AAVrh10 cap-
sids in serum.
Table S2. Neutralizing antibody titers against AAV9 and AAVrh10 cap-
sids in CSF.
Video S1. Subjective mobility observations in AAV-treated MPS VII dogs.
Materials and Methods
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